15-years experience of cataract and glaucoma surgery with phacoemulsification combined with non-penetrating deep sclerectomy and lens capsule drainage
Session Details
Session Title: Presented Poster Session: Glaucoma
Venue: Poster Village: Pod 2
First Author: : G.Solovyova RUSSIA
Co Author(s): : K. Pershin N. Pashinova A. Tsygankov L. Batalina
Abstract Details
Purpose:
Analysis of long-term results of cataract phacoemulsification combined with non-penetrating deep sclerectomy (NPDS) and lens capsule drainage.
Setting:
Eximer Eye Center, Moscow, Russian Federation
Methods:
The study included 67 patients (107 eyes) with cataract and glaucoma. Mean patient age at the time of surgery was 64.3 ± 8.1 (51-84) years. In all cases, the standard ophthalmological examination was performed. BCVA before surgery ranged from light perception to 1.0 (0.44±0.12). Mean preoperative IOP was 26.4±3.9 (16 to 45) mm Hg. I stage of glaucoma was determined in 18 eyes (16.8%), II stage 64 eyes (59.8%), III stage 20 eyes (18.7%) and IV stage 5 eyes (4.7%). A combined surgical treatment (phaco + NPDS + lens capsule drainage) was performed. Follow-up was 15 to 17 (15.8±0.9) years.
Results:
At the end of the observation period the average BCVA was 0.59±0.12, which is 0.15 higher than before surgery (p<0.05). The mean IOP was 17.8±3.1 (8 to 25) mm Hg, the difference with pre-operative parameters was statistically significant (8.6 mmHg; p<0.05). On average, patients received 1.4±0.6 (0 to 2) hypotensive drug instillations, which is 1.2 smaller than that before the operation, significance level trends (0.05
Conclusions:
The paper presents a surgical modification of the classical non-penetrating deep sclerectomy combined with cataract phacoemulsification and lens capsule drainage. A 15-years follow-up analysis is given. The progression of glaucomatous process at tolerant IOP was observed in 35.5% of cases, and stabilization - in 64.5% (n=69), of which 37 cases (53.6%) without the use of hypotensive drugs.The proposed combined surgery may be recommended for use in clinical practice for the treatment of patients with cataract and primary open angle glaucoma.
Financial Disclosure:
NONE
